Glucose metabolism via the pentose phosphate pathway (PPP) is typically upregulated in tumors, including gliomas. We previously showed that hyperpolarized δ-[1-13C]gluconolactone metabolism via the PPP to 6-phospho-[1-13C]gluconate (6PG) differentiates tumor from contralateral normal brain in preclinical glioma models. Here, we examined the ability of hyperpolarized δ-[1-13C]gluconolactone to probe response to temozolomide, which is a key chemotherapeutic drug for glioma patients. Our studies in live cells and rats bearing orthotopic gliomas indicate that 6PG production from hyperpolarized δ-[1-13C]gluconolactone serves as an early biomarker of response to temozolomide, a finding that has the potential to improve treatment response monitoring for glioma patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords